PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-100.00%
Both companies show declining revenue. Martin Whitman would check for industry-wide issues.
8.54%
Cost increase while GNPX reduces costs. John Neff would investigate competitive disadvantage.
-83.05%
Both companies show declining gross profit. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-18.94%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
28.45%
G&A growth 1.25-1.5x GNPX's 19.79%. Martin Whitman would scrutinize overhead control.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.25%
Operating expenses reduction while GNPX shows 0.18% growth. Joel Greenblatt would examine advantage.
-7.93%
Total costs reduction while GNPX shows 0.17% growth. Joel Greenblatt would examine advantage.
-100.00%
Both companies reducing interest expense. Martin Whitman would check industry trends.
8.54%
D&A growth while GNPX reduces D&A. John Neff would investigate differences.
7.52%
EBITDA growth while GNPX declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
7.21%
Operating income growth while GNPX declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-9.03%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
7.01%
Pre-tax income growth while GNPX declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-68.42%
Both companies reducing tax expense. Martin Whitman would check patterns.
7.01%
Net income growth while GNPX declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
8.82%
EPS growth 1.25-1.5x GNPX's 7.52%. Bruce Berkowitz would examine sustainability.
8.82%
Diluted EPS growth 1.25-1.5x GNPX's 7.52%. Bruce Berkowitz would examine sustainability.
0.91%
Share count reduction exceeding 1.5x GNPX's 8.81%. David Dodd would verify capital allocation.
0.91%
Diluted share reduction exceeding 1.5x GNPX's 8.80%. David Dodd would verify capital allocation.